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Liu JF, Jons C, Moss AJ, et al., for the International Long QT Syndrome Registry. Risk Factors for Recurrent Syncope
and Subsequent Fatal or Near-Fatal Events in Children and Adolescents With Long QT Syndrome. J Am Coll
Cardiol 2011;57:941–50.
In the above paper, on the first page, the following author affiliations were incorrect:
The affiliation notated by a double dagger should have been: ††Molecular Cardiology, IRCCS Fondazione Salvatore
Maugeri, Pavia, Italy.
Silvia G. Priori is also affiliated with the Department of Cardiology, University of Pavia, Pavia, Italy.
Peter J. Schwartz should not be affiliated with the Cardiovascular Genetic Program. His correct affiliations are:
Department of Cardiology, University of Pavia, Pavia, Italy; and the Fondazione IRCCS Policlinico S. Matteo, Pavia,
Italy.
The authors apologize for this error.
doi:10.1016/j.jacc.2011.03.003
Stamatakis E, Hamer M, Dunstan DW. Screen-Based Entertainment Time, All-Cause Mortality, and Cardiovascular
Events: Population-Based Study With Ongoing Mortality and Hospital Events Follow-Up. J Am Coll Cardiol
2011;57:292–9.
In this paper, both reference 29 and its citation on page 298 should be deleted. As this material has not been published, the
correct citation appears on page 298, at the top of the left column: “(Stamatakis et al., unpublished observations, January to
February 2010).”
We apologize for this error.
doi:10.1016/j.jacc.2011.03.007
Fifer KM, Qadir S, Subramanian S, et al. Positron Emission Tomography Measurement of Periodontal 18F-
Fluorodeoxyglucose Uptake Is Associated With Histologically Determined Carotid Plaque Inflammation. J Am Coll
Cardiol 2011;57:971– 6.
In this paper, one of the authors’ names appears incorrectly. Udo Hoffman, MD, MPH, should be changed to Udo
Hoffmann, MD, MPH.
The authors apologize for this error.
doi:10.1016/j.jacc.2011.03.009
Damman P, Beijk MAM, Kuijt WJ, et al. Multiple Biomarkers at Admission Significantly Improve the Prediction of
Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation
Myocardial Infarction. J Am Coll Cardiol 2011;57:29 –36.
In this paper, the following corrections are needed:
On page 29, in the first page abstract, in the last line of the Results section, the value for the net reclassification index
should be changed from “(0.494, p 0.001)” to “(0.481, p 0.001)” and the integrated discrimination improvement should
be changed from “(0.0295, p  0.01)” to “(0.0226, p  0.03).”
On page 31, in the right column, Results section, line 9, the sentence “There were clinically small, but statistically
significant, differences in hypercholesterolemia, history of coronary artery bypass grafting, and prevalence of anterior MI”
should be changed to “There were clinically small, but statistically significant, differences in hypercholesterolemia, history of
coronary artery bypass grafting, time to treatment, and prevalence of anterior MI.”
On page 32, in Table 1, under “Laboratory assessments,” the “Time to treatment” values should be “190 (133–273)” in
the study group and “161 (124–251)” in excluded patients, and the p value should be changed to “0.02.”
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April 19, 2011:1717–9On page 33, in the left column, 2nd line from the bottom, the text should be changed from “intermediate-risk (17.4%)”
to “intermediate-risk 20.3%.”
On page 33, in the right column, the section “Biomarkers and established risk factors” should be changed to read as follows:
Biomarkers and established prognostic factors. After adjustment for established risk factors, eGFR and NT-proBNP
remained significant predictors for mortality, while a trend toward higher mortality was observed with higher glucose values
(Table 3). An eGFR 60 ml/min was associated with a 3.57 increased mortality hazard (HR: 3.57, 95% CI: 1.57–8.11,
p  0.01). A glucose level 10 mmol/l (HR: 1.48, 95% CI: 0.83–2.64, p  0.19) was associated with a trend toward higher
ortality at the end of follow-up. Finally, a 2-fold increase in mortality was observed with NT-proBNP values 600 ng/l
p  0.01). Adding eGFR, NT-proBNP, and glucose to the established risk factors improved the prediction of mortality,
s shown by the increase in the Harrell’s C index (Table 5). Reclassification of patients who died or were alive at follow up
s presented by the NRI. Addition of each single biomarker (except glucose) or the 3 markers from our score significantly
mproved the reclassification of patients (p  0.001). The integrated discrimination significantly improved after addition of
T-proBNP, eGFR, or the 3 markers.
Because we hypothesized that the relationship between admission glucose levels and mortality differed between diabetic and
ondiabetic patients, we assessed the interaction between glucose and diabetes by testing the significance of this relation in the Cox
roportional-hazards model with established risk factors. No interaction was observed (p  0.85).
On page 35, in the right column, in the Study limitations section:
• In the 7th line from the top, the number of excluded patients should be changed from “279” to “249.”
• In the 9th line from the top, the following sentence should be deleted: “However, there were no statistically significant
differences between included and excluded patients with the exception of more prior coronary artery bypass grafting
procedures in the excluded patients.”
In addition, Figure 2, Table 3, and Table 5 should be replaced with the below.
he authors apologize for these errors.
doi:10.1016/j.jacc.2011.03.006
Hazard Ratios for Mortality in the Multimarker and Adjusted Multimarker ModelTable 3 Hazard Ratios for Mortality in the Multimarker and Adjusted ultimarker Model
Multimarker
Mortality
Multimarker Models (n  1,034)
p Value
Adjusted Multimarker
Model* (n  785)
p ValueHazard Ratio (95% CI) p Value Hazard Ratio (95% CI) Hazard Ratio (95% CI)
Troponin T (g/l)
0.05 Reference
0.05–0.23 1.16 (0.71–1.89) 0.55
0.24 1.41 (0.87–2.28) 0.17
Glucose (mmol/l)
8 Reference Reference Reference
8–9 1.92 (1.19–3.10) 0.01 1.94 (1.21–3.13) 0.01 1.07 (0.60–1.91) 0.82
10 2.77 (1.76–4.34) 0.001 2.83 (1.81–4.43) 0.001 1.48 (0.83–2.64) 0.19
NT-proBNP (ng/l)
150 Reference Reference Reference
150–599 1.55 (0.87–2.75) 0.14 1.74 (1.00–3.04) 0.05 1.43 (0.74–2.75) 0.28
600 2.75 (1.54–4.94) 0.001 3.45 (2.05–5.82) 0.001 2.39 (1.25–4.55) 0.01
eGFR (ml/min)
90 Reference Reference Reference
60–89 1.81 (1.12–2.92) 0.02 1.81 (1.12–2.93) 0.01 1.93 (0.95–3.91) 0.07
60 3.94 (2.37–6.42) 0.001 3.81 (2.32–6.26) 0.001 3.57 (1.57–8.11) 0.01
CRP (mg/l)
7 Reference
7 1.18 (0.80–1.73) 0.41
*Adjusted for age, BMI, history of diabetes or hypertension, systolic blood pressure and pulse, anterior myocardial infarction, and time to treatment. Two hundred forty nine patients were excluded because
of missing values. Excluded patients had a higher BMI, troponin T, and NT-proBNP; more often had a history of PCI/CABG; and had a lower systolic blood pressure.
BMI  body mass index; CABG  coronary artery bypass grafting; other abbreviations as in Tables 1 and 2.
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April 19, 2011:1717–9Discrimination of Cox Regression Models in Predicting Mortality in STEMI PatientsTable 5 Discrimination of Cox Regression Models in Predicting Mortality in STEMI Patients
Risk Factors and Biomarkers
Discrimination
Harrell’s C
index
Net Reclassification
Improvement p Value
Integrated Discrimination
Improvement p Value
Established risk factors 0.78 Reference Reference
Established risk factors plus troponin T 0.79 0.404 0.01 0.0004 0.92
Established risk factors plus glucose 0.79 0.017 0.90 0.0019 0.39
Established risk factors plus NT-proBNP 0.80 0.575 0.001 0.0159 0.01
Established risk factors plus eGFR 0.79 0.383 0.01 0.0147 0.12
Established risk factors plus CRP 0.79 0.489 0.001 0.0108 0.05
Established risk factors plus glucose, NT-proBNP, eGFR 0.81 0.481 0.001 0.0226 0.03
The NRI was defined as (pimproved_prediction_among_deceased pimproved_prediction_among_alive) (pworsened_prediction_among_deceased pworsened_prediction_among_alive), where p proportion of patients. The IDI was
i jefined as ( death (pnew(i)  pold(i))/n (deceased)) - ( alive (pnew(j)  pold(j))/n (alive)), where p  predicted probability of mortality.
Abbreviations as in Table 1.Low−risk group
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Figure 2 Kaplan-Meier Mortality Curves According to Risk Group
High-risk (multimarker score 6), intermediate-risk (multimarker score 5 or 6), and low-risk
(multimarker score 4) groups. Shown are Kaplan-Meier estimates. An overall log-rank test was used to compare groups.
